OncoZenge AB (publ) (STO:ONCOZ)
Sweden · Delayed Price · Currency is SEK 3.675
-0.145 (-3.80%)
Sep 4, 2026, 11:57 AM CET
OncoZenge AB Revenue
OncoZenge AB had revenue of 5.96M SEK in the quarter ending June 30, 2026, with 4,996.58% growth. This brings the company's revenue in the last twelve months to 5.97M, up 114.78% year-over-year. In the year 2025, OncoZenge AB had annual revenue of 2.78M with 278,300.00% growth.
Revenue (ttm)
5.97M
Revenue Growth
+114.78%
P/S Ratio
10.48
Revenue / Employee
5.97M
Employees
1
Market Cap
62.58M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.78M | 2.78M | 278,300.00% |
| Dec 31, 2024 | 1.00K | -2.00K | -66.67% |
| Dec 31, 2023 | 3.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nanologica AB | 136.17M |
| ExpreS2ion Biotech Holding AB | 24.25M |
| Fluicell AB | 22.19M |
| Biovica International AB | 13.49M |
| AcouSort AB | 9.31M |
| Spago Nanomedical AB | 3.81M |
| Simris Group AB (PUBL) | 1.39M |
| Pila Pharma AB | 275.74K |
OncoZenge AB News
- 8 days ago - OncoZenge AB Quarterly report: Q2 2026 - Filings
- 3 months ago - OncoZenge AB Quarterly report: Q1 2026 - Filings
- 5 months ago - OncoZenge AB Slides: FY 2026 - Filings
- 6 months ago - OncoZenge AB Quarterly report: Q4 2025 - Filings
- 6 months ago - OncoZenge AB Annual report: Q4 2025 - Filings
- 10 months ago - OncoZenge AB Quarterly report: Q3 2025 - Filings